Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25660320 | 0.90 | SMN1; SMN2 (0.41) | GAASMN1; SMN2KMT2ABRD4 | |
| SCHEMBL25522013 | 0.87 | PKM (0.42) | GAASMN1; SMN2KMT2ABRD4 | |
| SCHEMBL22320386 | 0.85 | HSD11B1 (0.41) | PIK3CDHSD11B1GAASMN1; SMN2PIK3CA | |
| SCHEMBL17452638 | 0.84 | MAPK1 (0.39) | PIK3CDHSD11B1GAASMN1; SMN2KMT2A | |
| SCHEMBL23135543 | 0.83 | KAT2B (0.42) | HSD11B1SMN1; SMN2CREBBPKMT2ABRD4 | |
| SCHEMBL20229800 | 0.83 | HSD11B1 (0.41) | PIK3CDHSD11B1GAASMN1; SMN2CREBBP | |
| SCHEMBL25396371 | 0.80 | PIK3CA (0.43) | SMN1; SMN2PIK3CA | |
| SCHEMBL22302817 | 0.80 | SSTR4 (0.39) | KMT2ABRD4 | |
| SCHEMBL23135532 | 0.80 | MAPK1 (0.41) | PIK3CDKMT2ABRD4 | |
| SCHEMBL22366382 | 0.76 | KDM4C (0.42) | PIK3CDHSD11B1PIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | PIK3CD 515/4885HSD11B1 21/4885GAA 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.